1.

Process for the production of a heterologous protein

Description of the achievement: The invention relates to a new process for the production of a biologically active heterologous protein. The process involves the performance of biosynthesis by adjusting conditions in such a way that the process enables the accumulation of correctly folded precursor of the heterologous protein already in inclusion bodies. The invention further comprises washing and solubilizing of the inclusion bodies, especially under non-denaturating conditions.

F.32 International patent

COBISS.SI-ID: 3015194

2.

Synthetic gene coding for human granulocyte-colony stimulating factor for the expression in E. coli

The invention relates to the synthetic gene coding for hG-CSF which enables expression in E.coli with improved expression level of the recombinant hG-CSF regarding the total cellular proteins after expression.

F.32 International patent

COBISS.SI-ID: 3015450

3.

Gastroresistant pharmaceutical dosage form comprising N-(2-(2-phthalimidoethoxy-acetyl)-L-alanyl-D-glutamic acid

The invention relates to pharmaceutical dosage forms which can be used for controlled and/or targeted delivery of the active substance to the selected regions of GIT of humans or animals. The pharmaceutical dosage forms will be mainly described by referring to the active substance N-(2-(2-phthalimidoethoxy)- acetyl)-L-alanyl-D-glutamic acid, although it can be applied for other active substances. An invention relates also to processes for obtaining said pharmaceutical dosage forms and the methods of treatment of chronic inflammatory diseases of humans and/or animals by using such forms.

F.32 International patent

COBISS.SI-ID: 1812337

4.

Selenium containing modifying agents and conjugates

Patent application relates to Selenium containing modifying reagents for site-specific PEGylation to cysteines. Stabilizing effect is achieved because bond is cleavable in the presence of small amounts of reducing agents enabling full release of fully active protein in blood. Sufficient amount of reducing agent is already present in the blood.

COBISS.SI-ID: 3912474

5.

Development of peptide mapping method for determination of identity of therapeutic protein

We developed peptide mapping method to determine identitiy of protein, monoclonal antibody. Peptide mapping method is demanding analytical method and its development requires mass spectropetry support which is achievement by itself. First mass spectrometry center for proteins has been established recentyl within CO CiPKeBiP.

COBISS.SI-ID: 34438149